In The News

Applied BioMath, LLC Provides Systems Pharmacology Modeling in Oncology for Antengene

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, was selected by Antengene Corporation to provide systems pharmacology modeling in immuno-oncology.   Applied BioMath developed a systems pharmacology model for a PDL1/41BB bispecific antibody, ATG-101, in immuno-oncology indications.

Applied BioMath, LLC Announces Collaboration with Asher Biotherapeutics for Systems Pharmacology Modeling in Oncology

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Asher Biotherapeutics for systems pharmacology modeling in solid tumors. "We have experience that development of a biotherapeutic has the best chance of success when the R&D proc

Applied BioMath, LLC Announces that Revitope Oncology is extending its Collaboration on Systems Pharmacology Modeling in Solid Tumors

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced that Revitope Oncology is extending its collaboration to develop a systems pharmacology model for Revitope's dual antigen targeting TwoGATE™ platform for solid tumor indications.

Applied BioMath, LLC Announces Collaboration with Antengene for Systems Pharmacology Modeling in Oncology

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Antengene Corporation for the development of a systems pharmacology model in immuno-oncology. Applied BioMath will develop a systems pharmacology model for a PDL1/41BB bispecific antibody, ATG-101, in immuno-oncology indications.

Applied BioMath, LLC Announces Two-Year Strategic Partnership with Xilio Therapeutics

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a two-year strategic partnership with Xilio Therapeutics.  Applied BioMath will provide a variety of services related to mathematical modeling, simulation, analysis, and visualization, which include syste

Applied BioMath, LLC Announces Collaboration with Cullinan Oncology

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Cullinan Oncology. Applied BioMath will develop a systems pharmacology model for CLN-049, a novel FLT3XCD3 bispecific antibody for Acute Myeloid Leukemia, being developed by Cullinan Florentine, a Cullinan Oncology company.

Applied BioMath, LLC Announces Collaboration with Flame Biosciences for Systems Pharmacology Modeling in Lung Cancer

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Flame Biosciences. Flame Biosciences selected Applied BioMath to develop systems pharmacology models for Flame Bioscience's leading therapeutic for the treatment of cancers that are driven by inflammation.

Applied BioMath, LLC Announces Collaboration with Verseau Therapeutics for System Pharmacology Modeling in Oncology

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their collaboration with Verseau Therapeutics for the development and delivery of a systems pharmacology model that will be used for efficacious dose prediction for the treatment of cancer. 

Applied BioMath, LLC Awarded Grant by the National Institutes of Health for Antibody Drug Conjugate Platform Model

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced they have been awarded a grant for the development of a software platform called Antibody Drug Conjugate (ADC) Workbench to facilitate efficient knowledge discovery and enable rapid knowledge qualificati

Applied BioMath, LLC Provides Systems Pharmacology Model to Support Fibrinolytic Therapy for Refractory COVID-19 Acute Respiratory Distress Syndrome

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced that it is creating a systems pharmacology model to support ongoing research into the compassionate care use of tissue plasminogen activator (tPA) as treatment of respiratory distress for patients with A

Applied BioMath, LLC Announces Collaboration with Zymeworks

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced the continuation of their collaboration with Zymeworks Inc.  Applied BioMath will design and deliver a systems pharmacology model for a therapeutic platform Zymeworks has in development.

Applied BioMath, LLC Announces Collaboration with Northern Biologics

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Northern Biologics for semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling of Northern Biologics' lead preclinical antibody for the treatment of cancer.  Northern Biologics will leverage Applied Biomath's modelling expertise to strengthen their understanding of key biological a